|Articles|December 1, 2001
Cyclosporine/PUVA approach to psoriasis raises cancer risk
Boston - Use of the immunosuppressant cyclosporine on patientswith psoriasis who have had substantial psoralen and ultra violet A lighttreatments show a sevenfold increase in the number of squamous cell cancertumors, according to Robert S. Stern, M.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
4
Meta-analysis Confirms Benefits of Roflumilast 0.3% Cream for PsO
5














